Application value of Presepsin in the diagnosis and prognosis of sepsis in children

The value of Presepsin biomarker in the diagnosis and prognostic assessment of sepsis in children: a single-center prospective cohort study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066871

Enrollment

Unknown

Registered

2022-12-20

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis in children

Interventions

Sepsis group:N/A

Severe sepsis and septic shock group:N/A

Healthy control group:N/A

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Children with sepsis admitted to the Children's Intensive Care Unit (PICU) of Tai 'an Central Hospital from January 2023 to January 2025. Criteria for admission: According to the Expert Consensus on the Diagnosis and treatment of septic shock in Children (2015 edition), patients were divided into sepsis group and severe sepsis/septic shock group according to their condition and guidelines. Healthy children in the same period were selected as control group.

Exclusion criteria

Exclusion criteria: Age =28 days, age >18 years; End-stage disease (advanced tumor of any type, end-stage chronic liver and kidney disease, severe heart failure); The presence of unrelieved hematological diseases and malignant tumors; Severe immunosuppression; Fatal congenital malformations or chromosomal abnormalities; The parents did not agree to participate in the study

Design outcomes

Primary

Measure	Time frame
Presepsin;	—

Countries

China

Contacts

Public ContactLiu Jing

Tai 'an City Central Hospital

liujingjingasthma@163.com15689670266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026